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The onset of venous thromboembolism, including pulmonary embo-
lism, represents a significant health burden affecting more than 1
million people annually worldwide. Current treatment options are
based on anticoagulation, which is suboptimal for preventing further
embolic events. In order to develop better treatments for thrombo-
embolism, we sought to understand the structural and mechanical
properties of blood clots and how this influences embolism in vivo.
We developed a murine model in which fibrin γ-chain cross-linking
by activated Factor XIII is eliminated (FGG3X) and applied methods to
study thromboembolism at whole-body and organ levels. We show
that FGG3X mice have a normal phenotype, with overall coagulation
parameters and platelet aggregation and function largely unaf-
fected, except for total inhibition of fibrin γ-chain cross-linking. Elim-
ination of fibrin γ-chain cross-linking resulted in thrombi with reduced
strength that were prone to fragmentation. Analysis of embolism
in vivo using Xtreme optical imaging and light sheet microscopy dem-
onstrated that the elimination of fibrin γ-chain cross-linking resulted in
increased embolizationwithout affecting clot size or lysis. Our findings
point to a central previously unrecognized role for fibrin γ-chain cross-
linking in clot stability. They also indirectly indicate mechanistic targets
for the prevention of thrombosis through selective modulation of fi-
brin α-chain but not γ-chain cross-linking by activated Factor XIII to
reduce thrombus size and burden, while maintaining clot stability and
preventing embolism.
fibrin | Factor XIII | thromboembolism | mechanical properties |
clot structure
Thrombosis is complicated by life-threatening embolic events,caused by parts of an intravascular blood clot breaking off
and traveling downstream to block other blood vessels supplying
critical organs. Thromboembolism occurs in both the venous and
arterial circulation and is associated with life-threatening pulmo-
nary embolism (PE) (1) and ischemic stroke (2). PE occurs when
thrombi in the deep veins of the limb embolise and passage with
the flowing blood through the inferior vena cava, the right atrium,
and ventricle of the heart to the lungs (3), causing pulmonary
hypertension and respiratory failure (4). Venous thromboembolism
(VTE), comprising deep vein thrombosis (DVT) and PE, which
globally affects over 1 million people each year (1), results in sub-
stantial healthcare costs (5) and is a major cause of death worldwide
(1, 6). Thromboembolism is clinically challenging to treat. Anti-
coagulation with vitamin K antagonists or direct oral anticoagulants
are used to treat VTE and prophylactically to prevent VTE re-
currence (7). In PE, localized thrombolysis with plasminogen
activators is challenging and often only used as a last resort to
help remove emboli resistant to anticoagulation (8). Improve-
ments in treatment and prevention of thromboembolic disor-
ders are therefore urgently needed.
Recent studies indicate that structural and functional prop-
erties of the clot could be critical in thromboembolism, and these
parameters may offer novel areas for therapeutic intervention.
Hypofibrinolysis was reported to increase the risk of a first DVT
(9), while changes in clot properties (increased clot formation rate
and fiber density, reduced fibrinolysis) promoted the recurrence of
DVT (10). Abnormalities in the establishment of clot viscoelastic
properties have been shown to increase risk of PE (11), and re-
duced clot elastic modulus has been associated with VTE recur-
rence (12). However, the exact mechanisms linking altered clot
properties to increased thromboembolic risk are unclear, and
therefore, treatment options remain limited and rely on dissolution
of fibrin networks and prevention of future clot formation, which
carry significant risk of bleeding events.
A key regulator of clot mechanical properties is coagulation
Factor XIII (FXIII), a protransglutaminase that is converted into
the active transglutaminase (FXIIIa) by thrombin (13). FXIIIa
catalyzes the formation of γ-glutamyl-e-lysine isopeptide bonds
between adjacent molecules within the fibrin fibers to substan-
tially increase elastic moduli and reduce storage moduli of both
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individual fibrin fibers and fibrin networks (14–17), therefore
making the clot more elastic and less viscous. FXIIIa cross-links
fibrin γ-chain residues Q398 and Q399 with K406 (18, 19), and
α-chain residues Q221, Q237, Q328, and Q366 with numerous
lysine residues (20–22). We previously demonstrated a critical
role for γ-chain cross-linking by FXIIIa in generating clot vis-
coelastic properties, in particular by increasing the elastic or
Young’s modulus, using a human recombinant fibrinogen γ-3X
(γ-Q398N/Q399N/K406R) mutant of the essential γ-chain cross-
linking sites (23–25).
The fibrin γ-chain cross-linking sites for FXIIIa are highly con-
served, and based on our previous in vitro data (23–25), we have
now generated a genetically modified mouse in which the fibrin
γ-chain cross-linking sites are mutated (FGG3X) to understand the
role of fibrin fiber cross-linking in predisposition to embolic dis-
ease. We confirm the importance of γ-chain cross-linking in en-
hancing clot mechanical properties in vivo. Furthermore, using two
protocols to study VTE, we demonstrate that lack of γ-chain cross-
linking by FXIIIa increases thromboembolism using advanced
whole-body and whole-organ imaging. We further show that fibrin
fibers lacking γ-chain cross-linking are more prone to rupture at
lower stress. These data indicate that fibrin γ-chain cross-linking
enhances the resistance of fibrin fibers to rupture, consequently
reducing clot fragmentation and thromboembolism.
Results
Generation and Characterization of the FGG3X Model. FGG3X mice
were generated on a C57BL/6 background, in which the con-
served fibrinogen γ-chain cross-linking residues Q398/Q399 and
K406 (SI Appendix, Fig. S1) were mutated to N and R residues,
respectively, using homologous recombination (SI Appendix, Fig.
S2). These mutations recapitulate the mutations generated in
our previously described recombinant human fibrinogen variant
(γ-3X), tested in vitro, which prevents γ-chain cross-linking by
FXIIIa (23). In comparison to wild type (WT), FGG3X mice
showed no difference in growth over 12 wk after birth (Fig. 1A).
In addition, no differences in bleeding time (Fig. 1B), fibrinogen
antigen level (Fig. 1C), FXIII activity (Fig. 1D), and whole blood
counts (Table 1) were observed, while there were no rebleeding
events in both WT and FGG3X mice. However, FGG3X mice
showed a total elimination of fibrin γ-chain cross-linking, while
α-chain cross-linking remained unaffected (Fig. 1E), in agree-
ment with our previous in vitro human recombinant fibrinogen
studies (23).
Whole–Blood Clot Firmness Is Decreased in FGG3X Mice, while Clot
Contraction Is Unaffected. We investigated the effects of the lack of
fibrin γ-chain cross-linking on whole–blood clot formation and
stability ex vivo. Rotational thromboelastometry (ROTEM) anal-
ysis was performed using both EXTEM (tissue factor Fig. 2A) and
FIBTEM (platelet inhibitor cytochalasin D, Fig. 2B) protocols to
investigate the role of fibrin γ-chain cross-linking in the presence or
absence of platelet activity, respectively. Whole–blood clotting time
was prolonged by 1.3-fold in EXTEM (Fig. 2C) and 1.6-fold (P <
0.01) in FIBTEM (Fig. 2E) for FGG3X compared to WT mice,
indicating a role for γ-chain cross-linking in early stabilization of
nascent fibrin fibers. Maximum clot firmness was decreased sig-
nificantly (P < 0.001) by 1.6- and 1.7-fold in EXTEM (Fig. 2D) and
FIBTEM (Fig. 2F), respectively, for FGG3X compared to WT
mice. These data demonstrate a role for fibrin γ-chain cross-linking
in providing firmness to the whole blood clot in the presence and
absence of platelets and are in agreement with our previous find-
ings of a decreased Young’s modulus for clots made with
recombinant human γQ398N/Q399N/K406R fibrinogen (23).
When a range of tissue plasminogen activator (tPA) concen-
tration was added to EXTEM (Fig. 2G), no difference in clot
lysis time (Fig. 2H) and other lysis parameters (Fig. 2 I–K) were
observed between FGG3X and WT mice, indicating no role for
fibrin γ-chain cross-linking in determining whole–blood clot
lysis efficiency.
Next, we examined whether the effects of FGG3X on clot
firmness by ROTEM could have been attributed to changes in clot
structure or platelet function. Clots were made with plasma col-
lected from both strains of mice and analyzed by turbidity mea-
surements and confocal microscopy. In vitro, turbidity analysis
(Fig. 3A) of plasma clots from FGG3X mice showed a 1.3-fold
increase in lag phase (Fig. 3B), in agreement with our previous
publication (24) and ROTEM data, but unchanged maximum ab-
sorbency (Fig. 3C) compared to WT mice, indicating no major
differences in fibrin fibers thickness and density. This was con-
firmed by confocal microscopy analysis of clots (Fig. 3 D and E),
where the fiber density (Fig. 3F) was similar between FGG3X and
WT mice. These data indicate that the architecture of clots from
FGG3X and WT mice is not different and therefore not respon-
sible for the differences in clot firmness observed by ROTEM.
Using flow cytometry, we found that agonist-induced platelet ex-
pression of P-selectin (Fig. 3G) and activation of αIIbβ3 (Fig. 3H) in
whole blood were indistinguishable between FGG3X and WT
mice. We next examined aggregation using thrombin and also
PAR4-specific peptide to account for any potential differences due
to the conversion of fibrinogen to fibrin and cross-linking of fibrin
by FXIII (Fig. 3I). The lag time to aggregation (Fig. 3 J andM) and
overall aggregation response (Fig. 3 L and O) was unchanged be-
tween FGG3X and WT mice, regardless of agonist. We observed a
minor reduction in the rate of aggregation for the FGG3X mice up
to 3 min, but afterward, the aggregation response was normal
(Fig. 3 I, K, and N). Furthermore, the presence of Tirofiban, an
inhibitor of αIIbβ3 binding to fibrin(ogen), abolished aggregation in
both mouse strains, confirming that fibrinogen-mediated aggrega-
tion of FGG3X platelets was largely unaffected (Fig. 3 I–O). To-
gether, these data show that the reduction in clot firmness by
ROTEM in the FGG3X model is attributable to the lack of fibrin
γ-chain cross-linking and not to major changes in platelet function
or clot architecture.
We then investigated the effect of the lack of fibrin γ-chain
cross-linking on whole–blood clot contraction, washed platelet
clot retraction, and in vivo clot size in an inferior vena cava stasis
model of thrombosis. We found that whole–blood clot contrac-
tion kinetics, final clot weight, and final serum hemoglobin
content (SI Appendix, Fig. S3 A–D) were comparable between
FGG3X and WT mice, indicating that the lack of γ-chain cross-
linking does not affect blood clot contraction, in agreement with
previous data showing that red blood cell retention is dependent
on α-chain cross-linking and not γ-chain cross-linking (26). The
ability of washed platelet clots to retract was also not affected by
the loss of fibrin γ-chain cross-linking (SI Appendix, Fig. S3 E and
F). These data were further supported by inferior vena cava li-
gation experiments (SI Appendix, Fig. S3 G and H), which
showed similar clot weight after 24 h between FGG3X and WT
mice, thus indicating that the lack of γ-chain cross-linking does
not affect overall clot formation or size in vivo.
FGG3X Mice Form Clots that Are Less Stable. A previously described
intravital microscopy model of venous thrombosis (27) using FeCl3
application to the femoral vein was used to study in vivo clot
formation. In this model, thrombus formation in the femoral vein
was followed over time (SI Appendix, Fig. S4), with measurements
of fibrin fluorescence, hence clot size, every 5 to 10 min over the
first hour in the FGG3X (Fig. 4A) andWT (Fig. 4B) mice. Despite
the average clot area for each time point being similar between
both strains, analyses of the individual kinetic data were consis-
tent, with FGG3X mice demonstrating more frequent drops in
clot size between subsequent time points compared with WTmice.
When this was quantified, with drops in clot size greater than 25%
between time points counted as embolic events (Fig. 4C), FGG3X
mice showed a significant 2.1-fold (P < 0.01) increase in embolic
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events compared to WT mice. The time for the first embolic event
to occur (Fig. 4D) was significantly shorter (1.8-fold, P < 0.05) in
FGG3X mice. The percentage of clot area loss per 5 min was also
quantified for all time points (Fig. 4E) and showed a significant
1.5-fold increase (P < 0.05) in the overall amount of clot embolism
in FGG3X mice compared to WT mice. These data suggest that
the lack of fibrin γ-chain cross-linking renders the clot more prone
to release fragments (emboli) during clot formation.
We next examined fibrin fiber mechanical behavior using lateral
atomic force microscopy, to probe fibers made with fibrinogen
purified from FGG3X and WTmice. Individual fibers were pulled
using a lateral force–sensing atomic force microscope until rup-
ture, and the resulting stress–strain curves (Fig. 4 F and G) were
analyzed. In the absence of cross-linking by FXIIIa, stiffness at low
(slope 1, Fig. 4H) and high (slope 2, Fig. 4I) strains, strain stiff-
ening (s2/s1, Fig. 4J), maximum stress before rupture (Fig. 4K),
and toughness (amount of energy absorbed prior to rupture;
Fig. 4L) were all similar between both types of fibrinogen. How-
ever, after cross-linking by FXIIIa, while initial stiffness was
slightly increased (1.3-fold), there was significant increase for large
strain stiffness (2.2-fold, P < 0.001), strain stiffening (1.7-fold, P <
0.0001), maximum stress before rupture (2.1-fold, P < 0.001), and
toughness (2.0-fold, P < 0.01) in WT but not FGG3X fibers.
Therefore, cross-linked FGG3X fibers were less stiff before rup-
ture (35%, P < 0001), exhibited reduced strain stiffening (75%,
P < 0.01), ruptured at a lower stress (45%, P < 0.001), and had
lower toughness (47%, P < 0.01) compared to WT fibers, indi-
cating that the lack of γ-chain cross-linking by FXIII renders the
FGG3X fibrin fibers more prone to rupture at lower stress relative
to WT.
Thromboembolism Models Show Increased Embolism in FGG3X Mice.
In order to investigate the effects of γ-chain cross-linking by
FXIIIa on clot stability and embolism in a pathophysiological
setting, we developed two protocols to specifically evaluate the
level of thromboembolism to the lungs (PE) from thrombi in
the inferior vena cava. First, we used optical imaging coupled to
X-ray to observe live appearance of emboli into the lungs of
mice undergoing inferior vena cava injury using FeCl3 (SI
Fig. 1. Mouse model characterization. WT and FGG3X mice showed no difference in growth, measured by weight (A), over the first 12 wk (n = 10). Tail
sectioning bleeding time (B), plasma fibrinogen concentration (C), and plasma FXIII activity measured by thrombin- and CaCl2-induced (2 U/mL and 10 mM)
pentylamine-biotin incorporation to fibrin (D) were not different between these two mouse strains. Fibrinogen, purified from plasma by ammonium sulfate
precipitation, was assayed for cross-linking of 5 μg fibrin by FXIII (10 μg/mL) activated with thrombin and CaCl2 (0.5 U/mL and 10 mM) (E) and showed full
inhibition of fibrin γ-chain cross-linking (no production of γ-γ dimers and continued presence of γ-monomers) in FGG3X, compared to WT, while the α-chain
cross-linking was not affected, as shown by the normal disappearance of α-monomers and appearance of polymers (n = 4). n = 8 (A–D) and 4 (E); [▲] males,
[•] females. The data are presented as mean ± SEM and analyzed by two-way ANOVA test (A) and Mann–Whitney U test (B–D).
Table 1. Hematological parameters in WT and FGG3X mice
Parameters WT FGG3X P values*
RBC (1012/mL) 5.34 ± 0.05 5.51 ± 0.07 0.127
HGB (g/dL) 8.83 ± 0.11 9.08 ± 0.11 0.226
HCT (%) 29.91 ± 0.32 29.86 ± 0.33 0.940
PLT (1011/mL) 5.99 ± 0.71 7.79 ± 0.47 0.083
WBC (109/mL) 3.33 ± 0.51 3.14 ± 0.22 0.775
LYM (%) 81.89 ± 1.23 84.41 ± 0.86 0.111
NEU (%) 8.48 ± 0.77 8.10 ± 0.53 0.857
MXD (%) 9.71 ± 0.71 7.58 ± 0.43 0.066
RBC: red blood cells; HGB: hemoglobin, HCT: hematocrit; PLT: platelets;
WBC: white blood cells; LYM: lymphocytes; NEU: neutrophils; and MXD:
mixed white blood cells.
*Data analyzed by Mann–Whitney U test. n = 8.
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Appendix, Fig. S5), after prior injection of fluorescent fibrino-
gen into the mice. The whole-body fluorescence levels in
FGG3X and WT mice were observed 0.5, 1, 2, 4, and 24 h
postinjury (Fig. 5A). We observed that fluorescence accumu-
lated specifically in the lungs over time after inferior vena cava
thrombosis due to clot embolism. In contrast, fibrin accumu-
lation was not observed elsewhere in the circulation of the mice.
Control experiments with only fluorophore injected (Fig. 5B) or
FeCl3 injury without fluorophore present (Fig. 5C) showed no
signal in these mice 2 h postinjury. Quantification of total fluo-
rescence in the lungs showed that 30 min postinjury, FGG3X mice
showed a significant 1.4-fold increase (P < 0.05) in clot emboli
compared to WT mice (Fig. 5D). This increase in fluorescence
intensity was also significantly higher in FGG3Xmice at 1 (1.4-fold,
P < 0.05), 2 (1.5-fold, P < 0.01), 4 (1.5-fold, P < 0.05), and 24 h
(1.6-fold, P < 0.05), compared to WT (Fig. 5D). Imaging was
performed in pairs of matching gender and weight. For each pair,
FGG3X mice showed higher fluorescence intensity in the
lungs than their WT counterparts at every time point (Fig. 5E).
Next, we used light sheet microscopy to image and quantify clot
emboli in the lungs of mice where the inferior vena cava was in-
jured with FeCl3 following tail vein injection of fluorescent
fibrinogen to visualize clots. Mice underwent whole-body fixation
and perfusion with fluorescent albumin (in gelatin) 1 h postsurgery
in order to visualize the vasculature. Lungs were imaged by light
sheet microscopy, and three-dimensional (3D) fluorescence re-
constructions of organs were created using IMARIS (Fig. 6A). In
this model, FGG3X mice showed a significant 1.5-fold increase
(P < 0.001) in pulmonary emboli count compared to WT (Fig. 6B).
The distribution of the emboli size (Fig. 6C) was also significantly
different (P < 0.05) between both strains, since FGG3X mice
exhibited a higher number of pulmonary emboli for each
volume range compared to WT mice. Together, these data
demonstrate that the lack of fibrin γ-chain cross-linking in-
creases embolism in the venous circulation, leading to an in-
creased number and volume of pulmonary thromboembolic
events.
Discussion
We describe a murine model of fibrinogen, FGG3X, in which all
three conserved fibrin γ-chain cross-linking sites have been mu-
tated, leading to a total lack of γ-chain cross-linking by FXIIIa.
While blood parameters were otherwise identical to that of the
Fig. 2. FGG3X mice form blood clots that are less firm thanWT mice. EXTEM (7 μL + 3 μL TBS) (A, C, and D) and FIBTEM (7 μL + 3 μL TBS) (B, E, and F) analysis of
whole blood (103 μL + 7 μL STARTEM) samples showed that clotting time (C and E) was not significantly different between WT and FGG3X mice, while
maximum clot firmness (D and F) was significantly decreased in FGG3X mice compared to WT mice. EXTEM in the presence of a range of tPA concentration
(2.5 to 100 nM) (G) showed that lysis time (H), % lysis at 30 (I), 45 (J), and 60 min (K), were similar between WT (dashed lines) and FGG3X mice (solid lines). n =
8; [▲] males, [•] females. The data analyzed are presented as mean ± SEM and analyzed by Mann–Whitney U test; **P < 0.01, ***P < 0.001.
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background C57BL/6 strain, and fibrin clot structure and platelet
physiology remained largely unchanged, ex vivo whole–blood clot
firmness was decreased in FGG3X mice due to the absence of
γ-chain cross-linking. We next developed specific protocols to
study thromboembolism using powerful X-ray and fluorescence
imaging combined with light sheet microscopy. We found that
during in vivo thrombus formation using an inferior vena cava
thromboembolism model, FGG3X produced clots with reduced
stability, which resulted in a larger number of pulmonary embolic
events. These data indicate that fibrin γ-chain cross-linking is
critical to thrombus stability in vivo and reduces clot fragmentation,
thereby reducing life-threatening thromboembolic disease. Future
treatment options should be developed to exploit this mechanism
for the treatment and prevention of fatal thromboembolic disease
Fig. 3. FGG3X mice have similar clot structure and platelet function compared with WT mice. Turbidity analysis of plasma (diluted one-sixth) activated with
thrombin and CaCl2 (0.1 U/mL and 10 mM) (A) showed a small increase in lag phase (B) for FGG3X mice but no difference in maximum absorbency (C)
compared to WT mice. Plasma clot structure (D and E) and fibrin fiber density (F), measured by confocal microscopy (one-eighth plasma, 25μg/mL Alexa-
Fluor488-fibrinogen, 0.05 U/mL thrombin, and 10 mM CaCl2), were also similar between FGG3X and WT mice (Scale bar, 25 μm). Platelet activation (P-Selectin
and αIIbβ3 activation analyzed by JON/A mAb binding induced by 0.1 U/mL thrombin for 20 min) (G and H) and aggregation (induced by 0.05 U/mL thrombin
[THR, Top], or 100 μM PAR4 [Bottom], over 10 min) (I) of FGG3X mice were similar compared to that of WT mice. The rate of aggregation was slightly slower
for FGG3X mice at 2 and 3 min (K and N), but the lag time (J and M) and final aggregation (L and O) were identical to that of WT mice. When 5 μg/mL
Tirofiban was added (I: solid lines without, broken lines with Tirofiban), aggregation was inhibited to a similar extent between FGG3X and WT mice. n = 8
(A–F), 4 (G and H), and 6 (I–O); [▲] males, [•] females. The data are presented as mean ± SEM and analyzed by Mann–Whitney U test (A–F) and two-way
ANOVA test (G–O); *P < 0.05, ***P < 0.001, ****P < 0.0001.
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by specifically targeting fibrin α-chain cross-linking–dependent
erythrocyte retention, therefore clot size and burden, while allow-
ing for normal FXIIIa-mediated fibrin γ-chain cross-linking to
prevent embolism.
Clinically, treatment of thrombosis is largely based on anti-
coagulation, with little attention for the quality or stability of the
blood clot. Clot quality and stability, however, have been reported
to play a role in thromboembolism (9–12), an important and
dangerous sequela of thrombosis, leading to PE. As such, it is
important to fully understand the role of fibrin cross-linking in the
formation and stability of thrombi and their subsequent emboli-
zation. On the basis of these considerations, we consider that a
more-complete understanding of the implications of cross-linking
by FXIIIa on clot stability and embolism is urgently needed in
Fig. 4. Clot stability and fiber resistance to rupture are reduced in FGG3X mice. Following injection of 100 μg AlexaFluor488-fibrinogen and injury to the
femoral vein with 10% FeCl3 for 3 min, clot size was measured over time by intravital fluorescence microscopy in WT (A) and FGG3X (B) mice, with the red line
representing the average clot area and bold lines representing clot size decreases greater than 25%/5 min (embolic event). The number of embolic events (C)
was significantly increased, the time for the first embolic event to occur (D) was significantly lower, while the overall size of the emboli (E) were significantly
larger in FGG3X mice compared to WT mice. Fibrin fiber pulling characteristics were measured by lateral atomic force microscopy using purified FGG3X and
WT fibrinogens in the absence (F) or presence (G) of FXIIIa. Low strain stiffness (H) was slightly increased, while maximal stiffness prior to rupture (I), strain
stiffening (J), maximum stress before rupture (K), and fiber toughness (L) were significantly increased by cross-linking in WT but not FGG3X fibrin. n = 8 (A–E)
and 18 to 22 (F–L); [▲] males, [•] females. The data are presented as mean ± SEM and analyzed by Mann–Whitney U test (C), χ2 test (D), Kolmogorov–
Smirnov test (E), and one-way ANOVA test (H–L); *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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order to optimize future treatment regimens for thrombosis and
thromboembolism.
We previously generated a recombinant human fibrinogen
variant γ-3X (23), in which all the three γ-chain cross-linking
sites were mutated (γQ398N/Q399N/K406R). This fibrinogen
allowed for careful and detailed dissection of the specific roles of
α–α and γ–γ cross-links in clot structure and mechanical prop-
erties in vitro (23–25). Injection of human fibrinogen γ-3X mu-
tant in fibrinogen−/− mice demonstrated that fibrin α-chain plays
a central role in red blood cell retention during whole–blood
clot contraction and is therefore a key determinant of clot and
thrombus size (26). Since the importance of fibrin γ-chain cross-
linking in clot stability has not yet been studied in vivo due to a
lack of an appropriate animal model, and since the γ-chain cross-
linking sites are highly conserved in human and mouse fibrino-
gens, we generated a FGG3X genetically modified murine model
in order to investigate the relevance of γ-chain cross-linking
in vivo. Except for a total lack of fibrin γ-chain cross-linking,
the basal phenotype of these mice was similar to WT, and (re)
bleeding was not affected, indicating that primary hemostasis
and α-chain cross-linking within the subsequent fibrin clot are
sufficient to prevent bleeding. We confirmed in this murine
model previous in vitro human data showing that a lack of fibrin
γ-chain cross-linking does not impair red blood cell retention
during clot contraction (26). Our results differ from that of
FXIII-A–deficient human (28) and mouse (29) clot retraction
assays, where cross-linking of both fibrin α- and γ-chain is fully
abolished by the absence of FXIII activity, resulting in impaired
clot retraction. We found that the presence of normal fibrin
α-chain cross-linking in the FGG3X mice maintains the whole–
blood clot contraction phenotype observed in WT mice. These
observations were confirmed by inferior vena cava stasis experi-
ments, showing that in a static in vivo environment (where clot
embolization is not possible due to complete vessel ligation), the
Fig. 5. Optical imaging analysis of PE in FGG3X and WT mice. Following injection of 100 μg AlexaFluor480-fibrinogen and injury to the inferior vena cava with
5%FeCl3 for 3 min, Xtreme (optical + X-ray) imaging of the whole animal was performed at 0.5, 1, 2, 4, and 24 h (A), pairing WT (Left) and FGG3X (Right) mice
by body weight (one representative pair shown). Injection of AF680-fibrinogen alone (B) or application of FeCl3 in the absence of AF
680-fibrinogen (C) did not
induce any fluorescence signal (2 h timepoint). Lungs total fluorescence intensity was measured for each time point and showed a significant increase of PE in
FGG3X mice compared to WT mice (D). For each pair, at each time point, FGG3X mice showed a higher fluorescence intensity than WT mice (E). n = 6; [▲]
males, [•] females. The data are presented as mean ± SEM and analyzed by two-way ANOVA test; *P < 0.05, **P < 0.01.
Duval et al. PNAS | 7 of 12
Elimination of fibrin γ-chain cross-linking by FXIIIa increases pulmonary embolism arising















lack of γ-chain cross-linking does not impact on the formation and
size of venous thrombi. Additionally, the mutations of γ-Q398N,
γ-Q399N, and γ-K406R residues, located near the αIIbβ3 binding
site (γ-404 to 411 in mouse and human) (30), did not affect washed
platelets activation, aggregation, and clot retraction. A study by
Jiroušková et al. (31) showed that an antibody (7E9) directed
against the fibrin γ-chain C terminus, which sterically hinders
fibrinogen–αIIbβ3 interaction and fibrin cross-linking by FXIIIa,
resulted in reduced platelet aggregation and clot contraction.
Additionally, in an arterial thrombosis model, γ-Δ5 mice (which
lack the N-terminal residues of the γ-chain responsible for αIIbβ3
interaction) and WT mice administered with the 7E9 antibody
formed smaller thrombi with limited embolization. Our data show
that the conservative Q-N and K-R mutations in the three cross-
linking sites for FXIIIa that are close to integrin binding site do
not influence platelet binding nor clot contraction, yet γ-chain
cross-linking is completely abolished. Importantly, in vivo experi-
ments using the FGG3X mice and intravital microscopy imaging
on clots formed in the femoral vein following application of FeCl3
(27) showed that these mice form clots that are less stable, most
likely due to the reduced toughness (increase rupture potential)
observed by single-fiber pulling experiments using lateral atomic
force microscopy, resulting in an increased number of embolic
events in the early stages of clot formation.
Next, two inferior vena cava thrombosis and PE protocols were
developed, showing a critical role for fibrin γ-chain cross-linking in
preventing clot embolism in the venous circulation. Our model
and protocol show that a loss of fibrin γ-chain cross-linking and
increased susceptibility to fiber rupture correlated with the for-
mation of less-stable venous thrombi that were more prone to
fragmentation and subsequent embolization to the lungs. We
found that FGG3X mice produced a higher degree of PE than
WT mice at all time points observed. At 2 h post–vena cava
thrombosis, the fluorescence intensity in the lungs of both FGG3X
and WT mice decreased at a similar rate, most likely due to fi-
brinolysis of the emboli taking place. The rate of lysis was similar
between both strains, in agreement with our ex vivo ROTEM data
showing that clot lysis was not affected by the lack of fibrin γ-chain
cross-linking. With clot lysis being unaffected, our data instead
indicate that clots without fibrin γ-chain cross-linking are more
readily deformed under shear stress, with dissociation of knob-
hole and other noncovalent bonds, which are not as strong as
covalent bonds (e.g., γ-chain cross-links present in WT but not
FGG3X fibrin) and hence rupture of individual fibers, which
render the clots more prone to fragmentation and embolism.
A paradigm is proposed in which in the absence of γ-chain
cross-linking, the force of flow applied to fibrin protofibrils
likely leads to the dissociation of the D–E–D interactions, slippage
of the fibrin molecules along the protofibrils, fiber rupture, and
permanent clot deformation (Fig. 7). Fibrin α-chain cross-linking
may in part rescue the integrity of the clots via intra- and inter-
protofibril cross-links. However, in places where those interactions
do not occur, due to the random nature of the α-chain cross-linking
orientation, rupture of the fibers results in subsequent clot embo-
lism. This phenomenon will be less common in clots from WT
mice, as fiber rupture and clot fragmentation are prevented by the
Fig. 6. Light sheet microscopy of clot emboli in the lungs of FGG3X and WT mice. Following injection of 100 μg AlexaFluor647-fibrinogen and injury to the
inferior vena cava with 5% FeCl3 for 3 min, perfusion fixation of the mice with PFA after 57 min, and injection of FITC-albumin in the circulation prior
collection and clearing of the lungs, light sheet fluorescence microscopy imaging of the lungs (A) showed that the total emboli count per mouse (B) was
significantly increased in FGG3X mice. The distribution of all the emboli volumes (C) showed that FGG3X mice produced significantly more emboli, irrespective
of their size, than WT mice (Scale bar, 1 mm). n = 8; [▲] males, [•] females. The data are presented as mean ± SEM and analyzed by Mann–Whitney U test (B)
and Kolmogorov–Smirnov test (C); *P < 0.05, ***P < 0.001.
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presence of fibrin γ-chain cross-links. This model is further sup-
ported by a previous study by Liu et al. on in vitro fibrin mechanical
properties, which concluded that “fast-forming γ–γ cross-links
along the axis may enhance elasticity and prevent rupture of the
(nascent) fibers” (17). Our data indicate that this is also the case
in vivo using protocols to study thromboembolism, suggesting a key
role for γ-chain cross-linking in the pathophysiology of this disease.
These findings are further supported by a recent clinical study
showing that plasma samples from patients with recurrent VTE
have reduced elastic modulus compared to samples from patients
with nonrecurrent VTE (12), indicating that optimal clot elasticity
is critical to prevent VTE recurrence.
Prior in vivo studies investigating thromboembolism involved
injection of exogenous clots or thrombotic substance in the ve-
nous system (e.g., thrombin or collagen/epinephrine) with the
use of histology to detect the emboli within the lungs (32). Shaya
et al. recently applied FeCl3 to the femoral vein to study thrombus
formation and performed histology of the lungs to analyze the
effect of dabigatran (a direct thrombin inhibitor) on PE (33).
Interestingly, these authors found that dabigatran decreased clot
stability and increased PE in this model, which they attributed to
reduced FXIII cross-linking activity since untreated FXIII−/−mice
showed similar rates of PE as WT mice treated with dabigatran.
We chose FeCl3 as trigger for thrombosis due to its reproducibility
in terms of the size of the ensuing thrombus. Furthermore, our
aim was to study clot stability and embolism rather than the de-
velopment of the clot itself, justifying the use of FeCl3 as a suitable
model to test our hypothesis. However, future studies may com-
bine whole-body/organ emboli imaging described here with other
models of venous thrombosis such as inferior vena cava ligation
and stenosis models, which have also been shown to lead to
embolization (34).
We developed and characterized methodological approaches
to study thromboembolism. We used live in vivo optical imaging
coupled with X-ray to analyze thromboembolism in real time in
living mice. Advantages of this method are that the fluorescently
labeled fibrin is stable enough to allow measurements for at least
24 h and that the method can be applied to other models of
thrombosis which tolerate animal recovery. Limitations are that
intensity measurements do not provide detailed information on
the number and volume of the emboli generated or their precise
location within the lungs and that imaging is only possible in those
parts of the body that are not masked by bones (e.g., the lungs but
not the brain) or very opaque tissues. Information on emboli to
organs covered by bone, however, can be provided by the second,
complementary imaging method that we used, involving terminal
Fig. 7. Fibrin γ-chain cross-linking increases clot stability and reduces embolism. Fibrinogen is a soluble heterotetrametric molecule, consisting of two α-, two
β-, and two γ-chains (A, Left), which is proteolytically converted by thrombin into insoluble fibrin. Fibrin monomers polymerize in a half-staggered ar-
rangement to form protofibrils which interact laterally via α-chains to form fibers (A, Middle). FXIIIa stabilizes the clots by forming longitudinal intra-
protofibril cross-links between glutamine 398 or 399 and lysine 406 (398/399 and 406 in human) of adjacent γ-chains, as well as lateral interprotofibril cross-
links between multiple glutamine and lysine residues of adjacent α-chains (A, Right). In normal conditions (B, WT mice), blood flow induces strain (F) on the
fibrin fibers, resulting in deformation of the clots which is reduced by γ-chain (intraprotofibril, yellow rectangles) and α-chain (intra- and interprotofibrils, blue
stars) cross-linking. Clots from FGG3X mice (C) exhibit a lack of γ-chain cross-linking, resulting in dissociation of the D–E–D interactions, slippage of the fibrin
molecules along the protofibrils, and permanent deformation and rupture of protofibrils and hence individual fibers. While fibrin α-chain cross-linking
partially rescues the integrity of the clots, the compromised γ-chain cross-linking predisposes to clot fragmentation and release of emboli (Insert) in places that
lack (randomly orientated) interprotofibril α-chain cross-links (images were created with BioRender.com).
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light sheet microscopy following perfusion fixation and tissue
clearing. The light sheet microscopy data 1 h postinjury were in
perfect agreement with the 1-h time point from the optical im-
aging experiments, showing that FGG3X mice demonstrate an
increased number of pulmonary emboli and that for each volume
bracket, FGG3X produced more emboli, which should result in an
overall higher fluorescence intensity. Advantages of this technique
are the detailed quantification of emboli numbers and volumes and
accurate location of these emboli in the organ as well as the im-
aging of any organ in the body, regardless of its location. Limita-
tions are that this is a terminal procedure, therefore requiring a
larger number of animals if more than one time point is required.
Thus, the combination of both light sheet microscopy and whole-
body combined optical and X-ray imaging provides powerful and
comprehensive analysis of thromboembolic disease. Furthermore,
it may be possible to combine both protocols in sequence, per-
forming optical imaging first, followed by light sheet imaging at the
terminal endpoint. This would require that the type of injury allows
for recovery and that fluorophores and filters are compatible with
both approaches.
Previous clot contraction assays and our current in vivo throm-
boembolization data provide strong evidence that fibrin α- and
γ-chain cross-linking play complementary roles in venous throm-
bosis via different mechanisms. Byrnes et al. showed that fibrin
α-chain (but not γ-chain) cross-linking plays an important role in
red blood cell retention within the clot (26), thereby increasing the
size of venous thrombi. Our study demonstrates that γ-chain cross-
linking is critical for the stability of venous thrombi, therefore
reducing breakdown and embolism. While anticoagulation is cur-
rently used as treatment for thromboembolic diseases, any possible
effects of this treatment on embolism have so far been largely ig-
nored. Based on our current data, and in agreement with Byrnes
et al. (26), we propose that specific inhibitors of fibrin α-chain
cross-linking should be developed to reduce red blood cell con-
tent within thrombi, therefore size and burden of venous thrombi.
Moreover, specific α-chain cross-linking inhibitors would not im-
pact on the critical fibrin γ-chain cross-linking by FXIIIa, thereby
preventing thromboembolic effects as shown in our current study.
In conclusion, we present the development and characterization
of a genetically modified murine model in which the residues re-
sponsible for fibrin γ-chain cross-linking are mutated. We also
developed and characterized protocols to study thromboembolism
using powerful imaging methods. These models demonstrate the
essential importance of γ-chain cross-linking in clot viscoelastic
properties. We show a critical role of fibrin γ-chain cross-linking
by FXIIIa in stabilizing clots and reducing thromboembolic events
in the venous (PE) circulation in vivo. These data demonstrate
important mechanisms related to clot mechanical properties in
thromboembolic disease, indicating a key future target for thera-
peutic intervention and prevention of this leading cause of death
that remains poorly treated to date.
Methods
Ethics. All procedures were approved by the University of Leeds and the
University of Sheffield Ethics Committees and performed under project
license numbers 70/8115 and P144DD0D6 (held by Stephen Wheatcroft at
Leeds University) and 70/8532 (held by Victoria Ridger, University of Sheffield)
according to the Home Office Animals (Scientific Procedures) Act 1986. Both
males and females were used, aged 6 to 8 wk at the time of the experiments.
Materials. Recombinant murine thrombin (Haematologic Technologies Inc) was
reconstituted to 250 U/mL in ddH2O and stored at−80 °C. Recombinant human
tPA (Pathway Diagnostics) was diluted in Tris-buffered saline (TBS; 0.05 M
Tris HCl, 0.1 M NaCl, pH 7.4) to 1,400 nM and stored at −80 °C. EZ-link
pentylamine-biotin (Thermo Fisher Scientific) was diluted in ddH2O to 30 μM
and stored at −20 °C. AlexaFluor488, AlexaFluor647, and AlexaFluor680 protein
labeling kits were purchased from Thermo Fisher Scientific. All other chemicals
were obtained from Sigma unless stated otherwise.
Generation and Maintenance of FGG3X Mice. A genetically modified murine
FGG3X line, in which the fibrinogen γ-chain cross-linking sites have been
mutated, were generated by GenOway as follows: Human residues γ-Q398,
γ-Q399, and γ-K406 (mature sequence) are conserved in murine fibrinogen
(γ-Q398, γ-Q399, and γ-K406; SI Appendix, Fig. S1), with the corresponding
codons located in exon 9 of the murine Fgg gene. Homologous recombination
in embryonic stem (ES) cells was performed using a targeting-vector–containing
region homologous to the murine genomic Fgg sequences. The targeting vec-
tor (ARI1-HR) was generated by cloning themouse genomic DNA encompassing
the murine Fgg gene regions surrounding the target exon 9 (exon 7 to 5′-UTR
[untranslated region]) into the targeting vector, inducing the three point mu-
tations (Q398N, Q399N, and K406R), and inserting a neomycin selection cassette
(Neo) (SI Appendix, Fig. S2). The vector was linearized and transfected into ES
cells by electroporation, and cells were selected for resistance to neomycin,
before the correct recombination events were validated by PCR and Southern
blot. The ES cells containing the correct recombination were then injected into
blastocysts (3.5-d-old embryos), which were subsequently implanted into C57BL/
6 pseudopregnant females, resulting in the generation of chimeric mice. Male
mice with chimerism rate above 50% were mated with C57BL/6-Cre females to
generate heterozygous mice carrying the Neo-excised knock-in allele, which
were bred for the generation of homozygous mice. Upon transfer to the Uni-
versity of Leeds, FGG3X mice were backcrossed onto our C57BL/6J strain over 10
generations and maintained in individually ventilated cages at 21 °C, 50 to 70%
humidity. The light/dark cycle was 12/12 h, andmice were fed on standard chow
diet ad-libitum. Experimental units were one mouse per cage.
Mouse Growth and Blood Sampling. WT and FGG3X mice were weighed once a
week, at the same time of the day from 2 to 12 wk old. Experiments were
performed with eight mice per group. For blood sampling, animals were bled
from the inferior vena cava under terminal anesthesia using 10% vol/vol
0.109 M sodium citrate as anticoagulant. Blood was centrifuged at 14,000 g for
10 min at room temperature (RT) for plasma preparation. The platelet-poor
plasma supernatant was collected, aliquoted, and stored at −80 °C.
Bleeding Time and Rebleeding Events. Tomeasure bleeding time, the distal 3-mm
segment of themouse tail tipwas sectionedusing a scalpel under anesthesia and
immersed in a microtube containing isotonic saline (37 °C) (35). Bleeding time
was determined using a stop clock. Measurement of rebleeding events was
performed using a method adapted from Molina et al. (36); the mice were
returned to individual cages 5 min after cessation of bleeding, and a filter paper
was applied to the end of the mouse tail every 15 min over a 1-h period. Ap-
pearance of fresh blood on the filter paper was counted as a rebleeding event.
Experiments were performed with eight mice per group.
Fibrinogen Levels and FXIII Activation Rate. Plasma fibrinogen levels were de-
termined using a murine fibrinogen total antigen enzyme-linked immunosor-
bent assay (ELISA) Kit (MyBioSource) following manufacturer’s instructions.
Measurement of FXIII activation was performed using a modified 5-(bio-
tinamido)pentylamine incorporation assay (27). Nunc-Immuno 96-MicroWell
plates were coated with 100 μL 10 μg/mL N,N-dimethylated casein for 40 min at
RT and blocked with 300 μL 1% bovine serum albumin (BSA) in TBS (pH 8.3) for
90 min at 37 °C. Plates were washed with 4× 300 μL TBS (pH 8.3) and 10 μL
plasma samples (diluted one-tenth in TBS [pH 8.3]) were added to the wells in
triplicate. A total of 90 μL activation mix (111 μM dithiothreitol [DTT], 0.3 μM
biotinylated pentylamine, 11 mM CaCl2, and 2.2 U/mL thrombin) were added
and the reactions were stopped at 0, 20, 40, 60, 80, 100, and 120 min by adding
200 μL 200 mM ethylenediaminetetraacetic acid. Plates were washed with 4×
300 μL 0.1% [vol/vol] Tween 20 in TBS (pH 8.3), and 100 μL 2μg/mL streptavidin
in 1% [wt/vol] BSA (in TBS-Tween) were added and incubated for 60 min at
37 °C. Following washes with 4× 300 μL TBS-Tween, 100 μL 1 mg/mL phos-
phatase substrate (in 1 M diethanolamine) were added for 7 min, and the re-
action was stopped by adding 100 μL 4 M NaOH. Absorbency was measured at
405 nm using a PowerWave HT Microplate Spectrophotometer (BioTek). The
rate of pentylamine incorporation over time was used as an indicator of FXIII
activation. Measurements were performed in triplicate, with eight mice
per group.
Fibrinogen Purification. Fibrinogen was purified from pooled mouse plasma by
ammonium and ethanol precipitations, using a protocol adapted from Dietrich
et al. (37). All steps were performed at 4 °C. A protease inhibitor mixture
(55 mM e-aminocaproic acid, 55 mM benzamidine, 11 μM pepstatin, 11 μM
leupeptin, and 1.1 mM phenylmethylsulfonyl fluoride, in TBS) was added (1:10
vol/vol) to plasma and 1 vol saturated ammonium sulfate (760 g/L) was slowly
(drop-by-drop) added to 3 vol plasma and incubated for 2 h. Following centri-
fugation at 12,000 g for 15 min, the pellet was resuspended in 2-(N-morpholino)
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ethanesulfonic acid (MES) buffer (55 mM e-aminocaproic acid, 55 mM ben-
zamidine, 1.1 μM pepstatin, 1.1 μM leupeptin, 110 μM phenylmethylsulfonyl
fluoride, 22 mM 2-(N-morpholino)ethanesulfonic acid, in ddH2O, pH 6.6),
and the whole process was repeated a second time, followed by pellet
resuspension and dialysis in TBS for 1 h. Then, 1 vol ice-cold 100% ethanol was
added drop-by-drop to 13 vol ice-cold suspension and incubated on ice for 1 h.
Following centrifugation at 12,000 g for 15 min, the pellet was resuspended
and dialyzed against TBS overnight before the concentration was determined
using a ND-100 Spectrophotometer (Thermo Fisher Scientific).
Fibrin Cross-Linking. Clottingmixtures (20 μL) containing fibrinogen (0.25mg/mL),
zymogen FXIII (10μg/mL), thrombin (0.5 U/mL), and CaCl2 (10 mM) were in-
cubated at 37 °C for 0, 2, 5, 10, 15, 20, 30, 60, and 120 min. Reactions were
stopped by adding 4× NuPAGE lithium dodecyl sulphate (LDS) Sample Buffer
(ThermoFisher Scientific) and 10× NuPAGE Sample Reducing Agent (Thermo
Fisher Scientific), immediately followed by heating at 90 °C for 10min. Samples
and molecular weight marker (Precision Plus Protein Dual Color Standards;
BioRad) were run onto a NuPAGE 4 to 12% Bis-Tris Protein Gel (Thermo Fisher
Scientific), and gels were stained using InstantBlue (Expedeon). Protein bands
were visualized and quantified using Genesys and GeneTools softwares (Syn-
gene). Band quantification for each lane was relative to the amount of B-β
chain staining. Experiments were performed in triplicate.
Fibrinogen Labeling. For in vivo experiments, fibrinogen purified from FGG3X
and WT mice was labeled with AlexaFluor 488, 647, or 680 depending on the
filters available for each setup. Labeling was performed following manu-
facturer’s instructions (Thermo Fisher Scientific).
Hematological Blood Parameters. Freshly obtained blood samples were run
onto a KX-21N Automated Hematology Analyzer (Sysmex). Discriminator val-
ues were changed for leukocyte counts as follows: LD 30 fl, T1 66 fl, and T2 84
fl. Experiments were performed in triplicate with eight mice per group.
Rotational Thromboelastometry. Freshly obtained blood samples were run on a
ROTEM-Delta (Werfen) for thromboelastic analysis. For clotting analysis, 103 μL
blood was mixed with 3 μL TBS, 7 μL EXTEM or FIBTEM, and 7 μL STARTEM
(CaCl2) reagents before data were acquired using the EXTEM and FIBTEM
channels (respectively). For lysis analysis, 107 μL blood was mixed with 7 μL
EXTEM and 7 μL STARTEM reagents and 3 μL tPA (final concentration range 2.5
to 100 nM) before data were acquired using the EXTEM channel. Measurements
were performed with eight mice per group.
Fibrin Polymerization and Clot Structure. Polymerization of fibrin was studied
by turbidity analysis as previously described (24). A total of 25 μL plasma
(one-third) were transferred into 384-well plates in triplicate. A total of 25 μL
CaCl2 and thrombin mix (0.1 U/mL and 10 mM final reaction concentrations)
were added to initiate clotting, and absorbency was measured at 340 nm every
12 s for 2 h at 32 °C using a PowerWave HT Microplate Spectrophotometer
(BioTek). Clot structure was analyzed by laser-scanning confocal microscopy,
as previously described (24). Plasma, AlexaFluor488-fibrinogen, CaCl2, and
thrombin (one-eighth, 25 μg/mL, 10 mM, and 0.05 U/mL final concentrations,
respectively) were mixed, transferred into the channel of an uncoated Ibidi
μ-slide VI (Thistle Scientific), and incubated in a dark humidity chamber for
60 min. Clots were imaged using an inverted Zeiss LSM-880 microscope (Carl
Zeiss) with a 40× oil immersion objective lens. Optical z-stacks were obtained
every 0.5 μm over 10 μm and combined into single projected images. Fiber
density was determined by counting the number of fibers crossing 10 arbitrary
lines of fixed length (200 μm) drawn through a single optical section. Experi-
ments were performed in triplicate with eight mice per group.
Platelet Functions. Platelet activation was measured in whole blood, supple-
mented with 10 μM Gly-Pro-Arg-Pro-NH2 and fluorescein isothiocyanate (FITC)-
conjugated anti–P-selectin (BD Biosciences) or PE-conjugated JON/A (anti-αIIbβ3;
Emfret) antibodies, incubated with or without thrombin (0.1 U/mL) for 20 min
at 37 °C (38). Whole blood was subsequently fixed with 1% paraformalde-
hyde (PFA) (in phosphate-buffered saline [PBS]) for 10 min and analyzed by
fluorescence-activated cell sorting using a CytoFLEX Flow Cytometer (Beck-
man Coulter). A compensation matrix was applied, and analysis was per-
formed with the CytExpert software version 2.1 (Beckman Coulter).
Experiments were performed in four mice per group.
Platelet aggregation was measured using suspended washed platelets.
Platelet-rich plasma was obtained by centrifugation of whole blood supple-
mented with 200 μL modified Tyrode’s buffer (MTB; 150 mM NaCl, 5 mM
Hepes, 0.55 mM NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM
d-glucose, pH 7.4) at 100 g for 5 min at RT. The resulting pellet was resuspended
in MTB and recentrifuged at 1,000 g in the presence of PGI2 (200 nM) for 6 min,
the washed platelet pellet was resuspended in MTB, and counts were adjusted
to 2.5 × 108 plt/mL using a Z1 Coulter Particle Counter (Beckman Coulter).
Platelet aggregation was performed using 250 μL washed platelets at 2 × 108
plt/mL, calibrated against MTB. Platelets were stimulated with thrombin
(0.05 U/mL) or PAR4 (100 μM) with or without the pretreatment of Tirofiban
(5 μg/mL), and aggregation was recorded under constant stirring conditions
(1,000 rpm) for 10 min at 37 °C using an AggRAM aggregometer (Helena Bio-
sciences Europe). Experiments were performed in six mice per group.
Intravital Microscopy. In vivo visualization of clot formation was performed as
previously described (27). Mice (6- to 8-wk-old) were anesthetized by intra-
peritoneal injection of ketamine/atropine/xylazine. The carotid artery was
cannulated to allow for maintenance of anesthesia and injection of 100 μg
AlexaFluor488-fibrinogen 5 min prior to exposure of the femoral vein and
application of a 10% [vol/vol] FeCl3-saturated filter paper (3 × 2 mm) for
3 min. Real-time observation of clot formation started 2 min after removal
of the FeCl3 filter paper and washing with isotonic saline using an upright
Nikon Eclipse E600-FN microscope (Nikon) equipped for fluorescence mi-
croscopy with a water-immersion 40/0.80-W objective. The green channel
(488 nm) was recorded using Slidebook Imaging Software version 5.0 (In-
telligent Imaging Innovation). Clot size for each time point was determined
as a combination of area and intensity of green pixels. Experiments were
performed with eight mice per group.
Lateral Atomic Force Microscopy. The mechanical response of individual fibrin
fibers upon lateral stretching was measured as described previously (17).
Briefly, clots were made on a striated surface (25, 39), with resulting fibers
forming over the trenches. Individual fibers were pulled laterally with the
atomic force microscope (AFM) cantilever, and the lateral deflection of the
cantilever was registered and used to calculate the force and the stress on
the fiber. Details are provided in SI Appendix, Methods.
Optical and X-ray Imaging. Mice (8-wk-old) were anesthetized with 1.5%
isoflurane (Piramal Critical Care) in oxygen (2 l/min flow rate). 100 μg of
AlexaFluor680-fibrinogen per 10 g of mouse body weight were injected into
the tail vein, and the abdomen, chest, and sides of the mice were shaved to
allow for imaging. The inferior vena cava was exposed after midline lapa-
rotomy and exteriorization of the bowels and separated from the abdomi-
nal aorta using a plastic spacer (40). A filter paper (2 × 3 mm) soaked with
5% FeCl3 was applied onto the isolated vessel for 3 min before removing the
filter paper and washing the abdominal cavity with saline. The bowels were
moved back into the abdominal cavity with saline, and the muscle and skin
layers were sutured sequentially. Animals were immediately injected with
100 μL 0.1 mg/mL Vetergesic (Ceva Animal Health Ltd) for pain relief. Using
the in vivo Xtreme II optical imaging system (Bruker), fluorescence (excita-
tion 680 nm, emission 700 nm) and X-ray in whole mice was imaged under
anesthesia at 0.5, 1, and 2 h postinjury, before animals were allowed to
recover, and then at 4 and 24 h postinjury. Animals were imaged in three
positions (frontal, sagittal left, and sagittal right) for each time point. Using
Molecular Imaging software version 7.5.2.22464 (Bruker) and X-ray images,
the lungs were delineated using the “ROI free form” tool (SI Appendix, Fig.
S5), and fluorescence intensity was quantified for each plane. The values for
each image plane were added, determining the total fluorescence intensity.
Each set of experiments comprised of one FGG3X and one WT mouse in pairs,
determined by gender and weight. Experiments were performed with six mice
per group.
Light SheetMicroscopy.Mice (6- to 8-wk-old)were anesthetizedby intraperitoneal
injection of ketamine/atropine/xylazine. AlexaFluor647-fibrinogen (100 μL per
10 g of body weight) was injected into the tail vein. The inferior vena cava was
isolated over a plastic sheet spacer (40), and a 2.5% FeCl3-soaked filter paper
(2 × 3 mm) was applied for 3 min. Remaining FeCl3 was washed off with isotonic
saline, and the mice were kept in the dark for a further 57 min. The mice were
then slowly perfused with 20 mL PBS (+50 U/mL heparin), 15 mL 4% PFA, and
10 mL hydrogel (41) (0.8 mg/mL FITC-Albumin, 2% wt/vol gelatin, in PBS). Mice
were immediately placed on ice for at least 30 min before the lungs were
harvested and transferred to 4% PFA overnight, at 4 °C, in the dark. All subse-
quent steps were performed in the dark. Next day, the lungs were dehydrated in
20, 40, 60, 80, and 100% methanol solutions (in ddH2O) for 1 h each, shaking at
200 rpm at RT, before being left overnight in fresh methanol solution. The left
and right lungs were then surgically separated before being optically cleared by
incubation in 66% dichloromethane (DCM)/34%methanol solution for 3 h at RT,
then twice in 100% DCM for 15 min, shaking at 200 rpm. Finally, the lungs were
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transferred into benzyl-ether (DBE) for at least for 72 h until imaging (42). The
lungs were imaged using a LaVision Ultramicroscope II light sheet microscope
coupled with a 0.63× MV PLAPO 2XC objective (Olympus) with lens protector,
and samples were immersed in an imaging chamber filled with ethyl cinnamate
(same refractive index as DBE). Samples excitation was performed with 470- and
630-nm lasers, producing a 5-μm-thick light sheet, with emitted light collected
using 525/550- and 680/630-nm filters, respectively. Two separate image z-stacks
for the green (hydrogel in blood vessels) and red (emboli) channels were gen-
erated using Imspector Pro software version 5.1.328 (Lavision Biotec GmbH).
Analysis of the datasets was performed using IMARIS software versin 9.3.0
(Oxford Instruments). The whole image stack was used to create a 3D image
reconstruction using identical image parameters for all samples. Volumetric
analysis of the emboli was performed using the “volume” tool, with the smallest
volume cutoff of 50 μm3 (based on smallest capillaries being around 4 to 5 μm in
diameter). The volume of individual emboli and the total number of emboli
were collected by the software. Experiments were performed with eight mice
per group, and data acquisition was blinded.
Data Analysis. All datasets were processed in GraphPad PRISM version 7.05 and
are presented as mean ± SEM. Data were statistically analyzed using Mann–
Whitney U test, unless otherwise stated: *P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001.
Data Availability. All study data are included in the article and/or SI Appendix.
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